Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study

Lung cancer is the leading cause of death worldwide. Non-small cell lung cancer (NSCLC) makes up about 80% of lung cancer cases, and up to 50% of these cancers are locally advanced when detected (1).